OSCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oscar Health Inc (OSCR) is not a strong buy for a beginner investor with a long-term focus at this moment. The technical indicators are bearish, there are no significant positive catalysts in recent news or trading trends, and the stock lacks strong proprietary trading signals. While the company shows improvement in financials and analysts have upgraded their ratings, the stock's current pre-market price trend and technical setup do not present an optimal entry point for long-term investment.
The technical indicators are bearish. The MACD histogram is negative and expanding downward, RSI is neutral at 23.533, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 12.001 and resistance at 13.709. The pre-market price is 11.815, down 0.21%, suggesting further weakness.
Analysts have recently upgraded the stock, citing attractive valuation and improved forward outlook. Revenue and net income have shown significant YoY improvement in Q4 2025.
No recent news or significant trading trends from hedge funds or insiders. The technical indicators are bearish, and the stock is underperforming in the pre-market. Congress trading data is absent, and the stock has a 70% chance of declining 5.46% in the next month.
In Q4 2025, revenue increased by 17.30% YoY to $2.81 billion, net income improved by 129.64% YoY to -$352.61 million, and EPS increased by 100% YoY to -$1.24. However, gross margin remains at 0%, showing no improvement.
Analysts have recently upgraded the stock. Raymond James upgraded it to Outperform with an $18 price target, citing margin recovery and attractive valuation. UBS and Barclays also upgraded their ratings, with price targets of $15 and $18, respectively. However, UBS maintains a Neutral rating, and the stock's forward outlook is mixed.
